Old things new view: Ascorbic acid protects the brain in neurodegenerative disorders

International Journal of Molecular Sciences

Volumn 16, Issue 12, 2015, Pages 28194-28217

  Covarrubias Pinto, Adriana ^a,b   Acuña, Aníbal Ignacio ^a,b   Beltrán, Felipe Andrés ^a,b   Torres Díaz, Leandro ^a,b   Castro, Maite Aintzane ^a,b  

^a UNIVERSIDAD AUSTRAL DE CHILE   (Chile)

^b Universidad Austral de Chile   (Chile)

Author keywords

Brain energy metabolism; Oxidative stress

Indexed keywords

ASCORBIC ACID; ANTIOXIDANT; NEUROPROTECTIVE AGENT; REACTIVE OXYGEN METABOLITE;

AMYOTROPHIC LATERAL SCLEROSIS; ANTIOXIDANT ACTIVITY; ASTROCYTE; BRAIN FUNCTION; CEREBROSPINAL FLUID ANALYSIS; DEGENERATIVE DISEASE; ENERGY METABOLISM; HOMEOSTASIS; HUMAN; NERVE DEGENERATION; NEUROTRANSMISSION; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; REVIEW; ANIMAL; BRAIN; CENTRAL NERVOUS SYSTEM; METABOLISM; NERVE CELL; OXIDATION REDUCTION REACTION; PATHOLOGY; SYNAPSE;

ANIMALS; ANTIOXIDANTS; ASCORBIC ACID; ASTROCYTES; BRAIN; CENTRAL NERVOUS SYSTEM; ENERGY METABOLISM; HUMANS; NEURODEGENERATIVE DISEASES; NEURONS; NEUROPROTECTIVE AGENTS; OXIDATION-REDUCTION; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; SYNAPSES;

EID: 84949034829     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms161226095     Document Type: Review

References (273)

1. Du, J.; Cullen, J.J.; Buettner, G.R. Ascorbic acid: Chemistry, biology and the treatment of cancer. Biochim. Biophys. Acta 2012, 1826, 443-457. [CrossRef] [PubMed]
2. Lachapelle, M.Y.; Drouin, G. Inactivation dates of the human and guinea pig vitamin C genes. Genetica 2011, 139, 199-207. [CrossRef] [PubMed]
3. Nishikimi, M.; Kawai, T.; Yagi, K. Guinea pigs possess a highly mutated gene for L-gulono--lactone oxidase, the key enzyme for L-ascorbic acid biosynthesis missing in this species. J. Biol. Chem. 1992, 267, 21967-21972. [PubMed]
4. May, J.M. Vitamin c transport and its role in the central nervous system. Subcell. Biochem. 2012, 56, 85-103. [PubMed]
5. Harrison, F.E.; May, J.M. Vitamin c function in the brain: Vital role of the ascorbate transporter SVCT2. Free Radic. Biol. Med. 2009, 46, 719-730. [CrossRef] [PubMed]
6. Frei, B.; England, L.; Ames, B.N. Ascorbate is an outstanding antioxidant in human blood plasma. Proc. Natl. Acad. Sci. USA 1989, 86, 6377-6381. [CrossRef] [PubMed]
7. Park, J.B.; Levine, M. Purification, cloning and expression of dehydroascorbic acid-reducing activity from human neutrophils: Identification as glutaredoxin. Biochem. J. 1996, 315, 931-938. [CrossRef] [PubMed]
8. Himmelreich, U.; Drew, K.N.; Serianni, A.S.; Kuchel, P.W. 13C NMR studies of vitamin C transport and its redox cycling in human erythrocytes. Biochemistry 1998, 37, 7578-7588. [CrossRef] [PubMed]
9. Ishikawa, T.; Casini, A.F.; Nishikimi, M. Molecular cloning and functional expression of rat liver glutathione-dependent dehydroascorbate reductase. J. Biol. Chem. 1998, 273, 28708-28712. [CrossRef] [PubMed]
10. Castro, M.A.; Pozo, M.; Cortes, C.; Garcia Mde, L.; Concha, I.I.; Nualart, F. Intracellular ascorbic acid inhibits transport of glucose by neurons, but not by astrocytes. J. Neurochem. 2007, 102, 773-782. [CrossRef] [PubMed]
11. Castro, M.A.; Angulo, C.; Brauchi, S.; Nualart, F.; Concha, I.I. Ascorbic acid participates in a general mechanism for concerted glucose transport inhibition and lactate transport stimulation. Pflugers Arch. 2008, 457, 519-528. [CrossRef] [PubMed]
12. Castro, M.A.; Beltrán, F.A.; Brauchi, S.; Concha, I.I. A metabolic switch in brain: Glucose and lactate metabolism modulation by ascorbic acid. J. Neurochem. 2009, 110, 423-440. [CrossRef] [PubMed]
13. Spector, R.; Lorenzo, A.V. Ascorbic acid homeostasis in the central nervous system. Am. J. Physiol. 1973, 225, 757-763. [PubMed]
14. Attwell, D.; Laughlin, S.B. An energy budget for signaling in the grey matter of the brain. J. Cereb. Blood Flow Metab. 2001, 21, 1133-1145. [CrossRef] [PubMed]
15. Alle, H.; Roth, A.; Geiger, J.R. Energy-efficient action potentials in hippocampal mossy fibers. Science 2009, 325, 1405-1408. [CrossRef] [PubMed]
16. Wilson, J.X. Antioxidant defense of the brain: A role for astrocytes. Can. J. Physiol. Pharmacol. 1997, 75, 1149-1163. [CrossRef] [PubMed]
17. Rodriguez, K.A.; Wywial, E.; Perez, V.I.; Lambert, A.J.; Edrey, Y.H.; Lewis, K.N.; Grimes, K.; Lindsey, M.L.; Brand, M.D.; Buffenstein, R.Walking the oxidative stress tightrope: A perspective from the naked mole-rat, the longest-living rodent. Curr. Pharm. Des. 2011, 17, 2290-2307. [CrossRef] [PubMed]
18. Sahoo, A.; Chainy, G.B. Alterations in the activities of cerebral antioxidant enzymes of rat are related to aging. Int. J. Dev. Neurosci. 1997, 15, 939-948. [CrossRef]
19. Ciani, E.; Groneng, L.; Voltattorni, M.; Rolseth, V.; Contestabile, A.; Paulsen, R.E. Inhibition of free radical production or free radical scavenging protects from the excitotoxic cell death mediated by glutamate in cultures of cerebellar granule neurons. Brain Res. 1996, 728, 1-6. [CrossRef]
20. Heafield, M.T.; Fearn, S.; Steventon, G.B.; Waring, R.H.; Williams, A.C.; Sturman, S.G. Plasma cysteine and sulphate levels in patients with motor neurone, parkinson's and alzheimer's disease. Neurosci. Lett. 1990, 110, 216-220. [CrossRef]
21. Halliwell, B. Oxidative stress and neurodegeneration: Where are we now? J. Neurochem. 2006, 97, 1634-1658. [CrossRef] [PubMed]
22. Goswami, A.; Dikshit, P.; Mishra, A.; Mulherkar, S.; Nukina, N.; Jana, N.R. Oxidative stress promotes mutant huntingtin aggregation and mutant huntingtin-dependent cell death by mimicking proteasomal malfunction. Biochem. Biophys. Res. Commun. 2006, 342, 184-190. [CrossRef] [PubMed]
23. Wyttenbach, A.; Sauvageot, O.; Carmichael, J.; Diaz-Latoud, C.; Arrigo, A.P.; Rubinsztein, D.C. Heat shock protein 27 prevents cellular polyglutamine toxicity and suppresses the increase of reactive oxygen species caused by huntingtin. Hum. Mol. Genet. 2002, 11, 1137-1151. [CrossRef] [PubMed]
24. Browne, S.E.; Bowling, A.C.; MacGarvey, U.; Baik, M.J.; Berger, S.C.; Muqit, M.M.; Bird, E.D.; Beal, M.F. Oxidative damage and metabolic dysfunction in huntington's disease: Selective vulnerability of the basal ganglia. Ann. Neurol. 1997, 41, 646-653. [CrossRef] [PubMed]
25. Warner, T.A.; Kang, J.Q.; Kennard, J.A.; Harrison, F.E. Low brain ascorbic acid increases susceptibility to seizures in mouse models of decreased brain ascorbic acid transport and alzheimer's disease. Epilepsy Res. 2015, 110, 20-25. [CrossRef] [PubMed]
26. Acuña, A.I.; Esparza, M.; Kramm, C.; Beltrán, F.A.; Parra, A.V.; Cepeda, C.; Toro, C.A.; Vidal, R.L.; Hetz, C.; Concha, I.I.; et al. A failure in energy metabolism and antioxidant uptake precede symptoms of huntington's disease in mice. Nat. Commun. 2013, 4, 2917. [CrossRef] [PubMed]
27. Mazziotta, J.C.; Phelps, M.E.; Pahl, J.J.; Huang, S.C.; Baxter, L.R.; Riege, W.H.; Hoffman, J.M.; Kuhl, D.E.; Lanto, A.B.;Wapenski, J.A.; et al. Reduced cerebral glucose metabolism in asymptomatic subjects at risk for huntington's disease. N. Engl. J. Med. 1987, 316, 357-362. [CrossRef] [PubMed]
28. Navarro, A.; Boveris, A. Brain mitochondrial dysfunction and oxidative damage in parkinson's disease. J. Bioenerg. Biomembr. 2009, 41, 517-521. [CrossRef] [PubMed]
29. Berger, T.M.; Polidori, M.C.; Dabbagh, A.; Evans, P.J.; Halliwell, B.; Morrow, J.D.; Roberts, L.J., 2nd; Frei, B. Antioxidant activity of vitamin C in iron-overloaded human plasma. J. Biol. Chem. 1997, 272, 15656-15660. [CrossRef] [PubMed]
30. Kiuchi, K.; Nishikimi, M.; Yagi, K. Purification and characterization of L-gulonolactone oxidase from chicken kidney microsomes. Biochemistry 1982, 21, 5076-5082. [CrossRef] [PubMed]
31. Grunewald, R.A. Ascorbic acid in the brain. Brain Res. Brain Res. Rev. 1993, 18, 123-133. [CrossRef]
32. Harrison, F.E.; Bowman, G.L.; Polidori, M.C. Ascorbic acid and the brain: Rationale for the use against cognitive decline. Nutrients 2014, 6, 1752-1781. [CrossRef] [PubMed]
33. Siliprandi, L.; Vanni, P.; Kessler, M.; Semenza, G. Na+-dependent, electroneutral L-ascorbate transport across brush border membrane vesicles from guinea pig small intestine. BBA Biomembr. 1979, 552, 129-142. [CrossRef]
34. Levine, M.; Wang, Y.; Padayatty, S.J.; Morrow, J. A new recommended dietary allowance of vitamin C for healthy young women. Proc. Nat. Acad. Sci. USA 2001, 98, 9842-9846. [CrossRef] [PubMed]
35. Carr, A.C.; Frei, B. Toward a new recommended dietary allowance for vitamin C based on antioxidant and health effects in humans. Am. J. Clin. Nutr. 1999, 69, 1086-1107. [PubMed]
36. Deruelle, F.; Baron, B. Vitamin C: Is supplementation necessary for optimal health? J. Altern. Complement. Med. 2008, 14, 1291-1298. [CrossRef] [PubMed]
37. Levine, G.N.; Frei, B.; Koulouris, S.N.; Gerhard, M.D.; Keaney, J.F., Jr.; Vita, J.A. Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 1996, 93, 1107-1113. [CrossRef] [PubMed]
38. Friedman, G.J.; Sherry, S.; Ralli, E.P. The mechanism of the excretion of vitamin c by the human kidney at low and normal plasma levels of ascorbic acid. J. Clin. Investig. 1940, 19, 685-689. [CrossRef] [PubMed]
39. Faaland, C.A.; Race, J.E.; Ricken, G.; Warner, F.J.; Williams, W.J.; Holtzman, E.J. Molecular characterization of two novel transporters from human and mouse kidney and from LLC-PK1 cells reveals a novel conserved family that is homologous to bacterial and aspergillus nucleobase transporters. BBA Gene Struct. Expr. 1998, 1442, 353-360. [CrossRef]
40. Daruwala, R.; Song, J.; Koh, W.S.; Rumsey, S.C.; Levine, M. Cloning and functional characterization of the human sodium-dependent vitamin C transporters HSVCT1 and HSVCT2. FEBS Lett. 1999, 460, 480-484. [CrossRef]
41. Tsukaguchi, H.; Tokui, T.; Mackenzie, B.; Berger, U.V.; Chen, X.Z.; Wang, Y.; Brubaker, R.F.; Hediger, M.A. A family of mammalian Na+-dependent L-ascorbic acid transporters. Nature 1999, 399, 70-75. [PubMed]
42. Castro, M.; Caprile, T.; Astuya, A.; Millan, C.; Reinicke, K.; Vera, J.C.; Vasquez, O.; Aguayo, L.G.; Nualart, F. High-affinity sodium-vitamin C co-transporters (SVCT) expression in embryonic mouse neurons. J. Neurochem. 2001, 78, 815-823. [CrossRef] [PubMed]
43. Garcia Mde, L.; Salazar, K.; Millan, C.; Rodriguez, F.; Montecinos, H.; Caprile, T.; Silva, C.; Cortes, C.; Reinicke, K.; Vera, J.C.; et al. Sodium vitamin C cotransporter SVCT2 is expressed in hypothalamic glial cells. Glia 2005, 50, 32-47. [CrossRef] [PubMed]
44. Takanaga, H.; Mackenzie, B.; Hediger, M.A. Sodium-dependent ascorbic acid transporter family SLC23. Pflugers Arch. 2004, 447, 677-682. [CrossRef] [PubMed]
45. Wilson, J.X. Regulation of vitamin C transport. Annu. Rev. Nutr. 2005, 25, 105-125. [CrossRef] [PubMed]
46. Lam, D.K.; Daniel, P.M. The influx of ascorbic acid into the rat's brain. Quart. J. Exp. Physiol. 1986, 71, 483-489. [CrossRef]
47. Angelow, S.; Haselbach, M.; Galla, H.J. Functional characterisation of the active ascorbic acid transport into cerebrospinal fluid using primary cultured choroid plexus cells. Brain Res. 2003, 988, 105-113. [CrossRef]
48. Nualart, F.; Mack, L.; Garcia, A.; Cisternas, P.; Bongarzone, E.R.; Heitzer, M.; Jara, N.; Martinez, F.; Ferrada, L.; Espinoza, F.; et al. Vitamin C transporters, recycling and the bystander effect in the nervous system: SVCT2 versus gluts. J. Stem Cell Res. Ther. 2014, 4, 209. [CrossRef] [PubMed]
49. Schenk, J.O.; Miller, E.; Gaddis, R.; Adams, R.N. Homeostatic control of ascorbate concentration in CNS extracellular fluid. Brain Res. 1982, 253, 353-356. [CrossRef]
50. Agus, D.B.; Gambhir, S.S.; Pardridge, W.M.; Spielholz, C.; Baselga, J.; Vera, J.C.; Golde, D.W. Vitamin C crosses the blood-brain barrier in the oxidized form through the glucose transporters. J. Clin. Investig. 1997, 100, 2842-2848. [CrossRef] [PubMed]
51. Taverna, R.D.; Langdon, R.G. Reversible association of cytochalasin B with the human erythrocyte membrane. Inhibition of glucose transport and the stoichiometry of cytochalasin binding. BBA Biomembr. 1973, 323, 207-219. [CrossRef]
52. Agus, D.B.; Vera, J.C.; Golde, D.W. Stromal cell oxidation: A mechanism by which tumors obtain vitamin C. Cancer Res. 1999, 59, 4555-4558. [PubMed]
53. Nualart, F.J.; Rivas, C.I.; Montecinos, V.P.; Godoy, A.S.; Guaiquil, V.H.; Golde, D.W.; Vera, J.C. Recycling of vitamin C by a bystander effect. J. Biol. Chem. 2003, 278, 10128-10133. [CrossRef] [PubMed]
54. Rice, M.E. Ascorbate regulation and its neuroprotective role in the brain. Trends Neurosci. 2000, 23, 209-216. [CrossRef]
55. Rice, M.E.; Russo-Menna, I. Differential compartmentalization of brain ascorbate and glutathione between neurons and glia. Neuroscience 1998, 82, 1213-1223. [CrossRef]
56. Milby, K.; Oke, A.; Adams, R.N. Detailed mapping of ascorbate distribution in rat brain. Neurosci. Lett. 1982, 28, 169-174. [CrossRef]
57. Stamford, J.A.; Kruk, Z.L.; Millar, J. Regional differences in extracellular ascorbic acid levels in the rat brain determined by high speed cyclic voltammetry. Brain Res. 1984, 299, 289-295. [CrossRef]
58. Miele, M.; Fillenz, M. In vivo determination of extracellular brain ascorbate. J. Neurosci. Methods 1996, 70, 15-19. [CrossRef]
59. Hediger, M.A. New view at C. Nat. Med. 2002, 8, 445-446. [CrossRef] [PubMed]
60. Basse-Tomusk, A.; Rebec, G.V. Regional distribution of ascorbate and 3,4-dihydroxyphenylacetic acid (DOPAC) in rat striatum. Brain Res. 1991, 538, 29-35. [CrossRef]
61. Ghasemzadeh, B.; Cammack, J.; Adams, R.N. Dynamic changes in extracellular fluid ascorbic acid monitored by in vivo electrochemistry. Brain Res. 1991, 547, 162-166. [CrossRef]
62. O'Neill, R.D.; Fillenz, M.; Sundstrom, L.; Rawlins, J.N. Voltammetrically monitored brain ascorbate as an index of excitatory amino acid release in the unrestrained rat. Neurosci. Lett. 1984, 52, 227-233. [CrossRef]
63. Boutelle, M.G.; Svensson, L.; Fillenz, M. Rapid changes in striatal ascorbate in response to tail-pinch monitored by constant potential voltammetry. Neuroscience 1989, 30, 11-17. [CrossRef]
64. Carr, A.; Frei, B. Does vitamin C act as a pro-oxidant under physiological conditions? FASEB J. 1999, 13, 1007-1024. [PubMed]
65. Maellaro, E.; del Bello, B.; Sugherini, L.; Santucci, A.; Comporti, M.; Casini, A.F. Purification and characterization of glutathione-dependent dehydroascorbate reductase from rat liver. Biochem. J. 1994, 301, 471-476. [CrossRef] [PubMed]
66. Washburn, M.P.; Wells, W.W. Identification of the dehydroascorbic acid reductase and thioltransferase (glutaredoxin) activities of bovine erythrocyte glutathione peroxidase. Biochem. Biophys. Res. Commun. 1999, 257, 567-571. [CrossRef] [PubMed]
67. Guaiquil, V.H.; Farber, C.M.; Golde, D.W.; Vera, J.C. Efficient transport and accumulation of vitamin C in Hl-60 cells depleted of glutathione. J. Biol. Chem. 1997, 272, 9915-9921. [PubMed]
68. May, J.M.; Qu, Z.C.; Mendiratta, S. Protection and recycling of α-tocopherol in human erythrocytes by intracellular ascorbic acid. Arch. Biochem. Biophys. 1998, 349, 281-289. [CrossRef] [PubMed]
69. Savini, I.; Duflot, S.; Avigliano, L. Dehydroascorbic acid uptake in a human keratinocyte cell line (HaCaT) is glutathione-independent. Biochem. J. 2000, 345(3), 665-672. [CrossRef] [PubMed]
70. Nualart, F.; Salazar, K.; Oyarce, K.; Cisternas, P.; Jara, N.; Silva-Alvarez, C.; Pastor, P.; Martinez, F.; Garcia, A.; Garcia-Robles Mde, L.; et al. Typical and atypical stem cells in the brain, vitamin C effect and neuropathology. Biol. Res. 2012, 45, 243-256. [CrossRef] [PubMed]
71. Rumsey, S.C.; Kwon, O.; Xu, G.W.; Burant, C.F.; Simpson, I.; Levine, M. Glucose transporter isoforms GLUT1 and GLUT3 transport dehydroascorbic acid. J. Biol. Chem. 1997, 272, 18982-18989. [CrossRef] [PubMed]
72. Vera, J.C.; Rivas, C.I.; Fischbarg, J.; Golde, D.W. Mammalian facilitative hexose transporters mediate the transport of dehydroascorbic acid. Nature 1993, 364, 79-82. [CrossRef] [PubMed]
73. Makar, T.K.; Nedergaard, M.; Preuss, A.; Gelbard, A.S.; Perumal, A.S.; Cooper, A.J. Vitamin E, ascorbate, glutathione, glutathione disulfide, and enzymes of glutathione metabolism in cultures of chick astrocytes and neurons: Evidence that astrocytes play an important role in antioxidative processes in the brain. J. Neurochem. 1994, 62, 45-53. [CrossRef] [PubMed]
74. Desagher, S.; Glowinski, J.; Premont, J. Astrocytes protect neurons from hydrogen peroxide toxicity. J. Neurosci. 1996, 16, 2553-2562. [PubMed]
75. Dringen, R.; Kussmaul, L.; Gutterer, J.M.; Hirrlinger, J.; Hamprecht, B. The glutathione system of peroxide detoxification is less efficient in neurons than in astroglial cells. J. Neurochem. 1999, 72, 2523-2530. [CrossRef] [PubMed]
76. Rohl, C.; Armbrust, E.; Herbst, E.; Jess, A.; Gulden, M.; Maser, E.; Rimbach, G.; Bosch-Saadatmandi, C. Mechanisms involved in the modulation of astroglial resistance to oxidative stress induced by activated microglia: Antioxidative systems, peroxide elimination, radical generation, lipid peroxidation. Neurotox. Res. 2010, 17, 317-331. [CrossRef] [PubMed]
77. Macco, R.; Pelizzoni, I.; Consonni, A.; Vitali, I.; Giacalone, G.; Martinelli Boneschi, F.; Codazzi, F.; Grohovaz, F.; Zacchetti, D. Astrocytes acquire resistance to iron-dependent oxidative stress upon proinflammatory activation. J. Neuroinflamm. 2013, 10, 130. [CrossRef] [PubMed]
78. Almeida, A.; Almeida, J.; Bolanos, J.P.; Moncada, S. Different responses of astrocytes and neurons to nitric oxide: The role of glycolytically generated ATP in astrocyte protection. Proc. Natl. Acad. Sci. USA 2001, 98, 15294-15299. [CrossRef] [PubMed]
79. Garcia-Nogales, P.; Almeida, A.; Bolanos, J.P. Peroxynitrite protects neurons against nitric oxide-mediated apoptosis. A key role for glucose-6-phosphate dehydrogenase activity in neuroprotection. J. Biol. Chem. 2003, 278, 864-874. [CrossRef] [PubMed]
80. Ben-Yoseph, O.; Boxer, P.A.; Ross, B.D. Assessment of the role of the glutathione and pentose phosphate pathways in the protection of primary cerebrocortical cultures from oxidative stress. J. Neurochem. 1996, 66, 2329-2337. [CrossRef] [PubMed]
81. Lovatt, D.; Sonnewald, U.; Waagepetersen, H.S.; Schousboe, A.; He, W.; Lin, J.H.; Han, X.; Takano, T.; Wang, S.; Sim, F.J.; et al. The transcriptome and metabolic gene signature of protoplasmic astrocytes in the adult murine cortex. J. Neurosci. 2007, 27, 12255-12266. [CrossRef] [PubMed]
82. Cahoy, J.D.; Emery, B.; Kaushal, A.; Foo, L.C.; Zamanian, J.L.; Christopherson, K.S.; Xing, Y.; Lubischer, J.L.; Krieg, P.A.; Krupenko, S.A.; et al. A transcriptome database for astrocytes, neurons, and oligodendrocytes: A new resource for understanding brain development and function. J. Neurosci. 2008, 28, 264-278. [CrossRef] [PubMed]
83. Astuya, A.; Caprile, T.; Castro, M.; Salazar, K.; Garcia Mde, L.; Reinicke, K.; Rodriguez, F.; Vera, J.C.; Millan, C.; Ulloa, V.; et al. Vitamin C uptake and recycling among normal and tumor cells from the central nervous system. J. Neurosci. Res. 2005, 79, 146-156. [CrossRef] [PubMed]
84. Yusa, T. Increased extracellular ascorbate release reflects glutamate re-uptake during the early stage of reperfusion after forebrain ischemia in rats. Brain Res. 2001, 897, 104-113. [CrossRef]
85. Patterson, J.W.; Mastin, D.W. Some effects of dehydroascorbic acid on the central nervous system. Am. J. Physiol. 1951, 167, 119-126. [PubMed]
86. Deponte, M. Glutathione catalysis and the reaction mechanisms of glutathione-dependent enzymes. BBA Gen. Subj. 2013, 1830, 3217-3266. [CrossRef] [PubMed]
87. Winkler, B.S.; Orselli, S.M.; Rex, T.S. The redox couple between glutathione and ascorbic acid: A chemical and physiological perspective. Free Radic. Biol. Med. 1994, 17, 333-349. [CrossRef]
88. Wells, W.W.; Xu, D.P.; Yang, Y.F.; Rocque, P.A. Mammalian thioltransferase (glutaredoxin) and protein disulfide isomerase have dehydroascorbate reductase activity. J. Biol. Chem. 1990, 265, 15361-15364. [PubMed]
89. Wells, W.W.; Xu, D.P. Dehydroascorbate reduction. J. Bioenerg. Biomembr. 1994, 26, 369-377. [CrossRef] [PubMed]
90. Linster, C.L.; van Schaftingen, E. Vitamin C. Biosynthesis, recycling and degradation in mammals. FEBS J. 2007, 274, 1-22. [CrossRef] [PubMed]
91. Board, P.G.; Coggan, M.; Chelvanayagam, G.; Easteal, S.; Jermiin, L.S.; Schulte, G.K.; Danley, D.E.; Hoth, L.R.; Griffor, M.C.; Kamath, A.V.; et al. Identification, characterization, and crystal structure of the ! class glutathione transferases. J. Biol. Chem. 2000, 275, 24798-24806. [CrossRef] [PubMed]
92. Whitbread, A.K.; Masoumi, A.; Tetlow, N.; Schmuck, E.; Coggan, M.; Board, P.G. Characterization of the ! class of glutathione transferases. Methods Enzymol. 2005, 401, 78-99. [PubMed]
93. Del Bello, B.; Maellaro, E.; Sugherini, L.; Santucci, A.; Comporti, M.; Casini, A.F. Purification of NADPH-dependent dehydroascorbate reductase from rat liver and its identification with 3 α-hydroxysteroid dehydrogenase. Biochem. J. 1994, 304, 385-390. [CrossRef] [PubMed]
94. Mendiratta, S.; Qu, Z.C.; May, J.M. Enzyme-dependent ascorbate recycling in human erythrocytes: Role of thioredoxin reductase. Free Radic. Biol. Med. 1998, 25, 221-228. [CrossRef]
95. Rose, R.C. Cerebral metabolism of oxidized ascorbate. Brain Res. 1993, 628, 49-55. [CrossRef]
96. Dragan, M.; Dixon, S.J.; Jaworski, E.; Chan, T.S.; O'Brien, P.J.;Wilson, J.X. Coenzyme Q1 depletes NAD(P)H and impairs recycling of ascorbate in astrocytes. Brain Res. 2006, 1078, 9-18. [CrossRef] [PubMed]
97. Siushansian, R.; Tao, L.; Dixon, S.J.; Wilson, J.X. Cerebral astrocytes transport ascorbic acid and dehydroascorbic acid through distinct mechanisms regulated by cyclic AMP. J. Neurochem. 1997, 68, 2378-2385. [CrossRef] [PubMed]
98. Tanaka, J.; Toku, K.; Zhang, B.; Ishihara, K.; Sakanaka, M.; Maeda, N. Astrocytes prevent neuronal death induced by reactive oxygen and nitrogen species. Glia 1999, 28, 85-96. [CrossRef]
99. Gegg, M.E.; Beltran, B.; Salas-Pino, S.; Bolanos, J.P.; Clark, J.B.; Moncada, S.; Heales, S.J. Differential effect of nitric oxide on glutathione metabolism and mitochondrial function in astrocytes and neurones: Implications for neuroprotection/neurodegeneration? J. Neurochem. 2003, 86, 228-237. [CrossRef] [PubMed]
100. Dringen, R.; Pfeiffer, B.; Hamprecht, B. Synthesis of the antioxidant glutathione in neurons: Supply by astrocytes of CysGly as precursor for neuronal glutathione. J. Neurosci. 1999, 19, 562-569. [PubMed]
101. Langeveld, C.H.; Jongenelen, C.A.; Schepens, E.; Stoof, J.C.; Bast, A.; Drukarch, B. Cultured rat striatal and cortical astrocytes protect mesencephalic dopaminergic neurons against hydrogen peroxide toxicity independent of their effect on neuronal development. Neurosci. Lett. 1995, 192, 13-16. [CrossRef]
102. Fujita, T.; Tozaki-Saitoh, H.; Inoue, K. P2y1 receptor signaling enhances neuroprotection by astrocytes against oxidative stress via il-6 release in hippocampal cultures. Glia 2009, 57, 244-257. [CrossRef] [PubMed]
103. Chen, Y.; Vartiainen, N.E.; Ying, W.; Chan, P.H.; Koistinaho, J.; Swanson, R.A. Astrocytes protect neurons from nitric oxide toxicity by a glutathione-dependent mechanism. J. Neurochem. 2001, 77, 1601-1610. [CrossRef] [PubMed]
104. Lucius, R.; Sievers, J. Postnatal retinal ganglion cells in vitro: Protection against reactive oxygen species (ROS)-induced axonal degeneration by cocultured astrocytes. Brain Res. 1996, 743, 56-62. [CrossRef]
105. Wilson, J.X.; Peters, C.E.; Sitar, S.M.; Daoust, P.; Gelb, A.W. Glutamate stimulates ascorbate transport by astrocytes. Brain Res. 2000, 858, 61-66. [CrossRef]
106. Selkirk, J.V.; Nottebaum, L.M.; Vana, A.M.; Verge, G.M.; Mackay, K.B.; Stiefel, T.H.; Naeve, G.S.; Pomeroy, J.E.; Petroski, R.E.; Moyer, J.; et al. Role of the GLT-1 subtype of glutamate transporter in glutamate homeostasis: The GLT-1-preferring inhibitor way-855 produces marginal neurotoxicity in the rat hippocampus. Eur. J. Neurosci. 2005, 21, 3217-3228. [CrossRef] [PubMed]
107. Bak, L.K.; Schousboe, A.; Waagepetersen, H.S. The glutamate/gaba-glutamine cycle: Aspects of transport, neurotransmitter homeostasis and ammonia transfer. J. Neurochem. 2006, 98, 641-653. [CrossRef] [PubMed]
108. Miele, M.; Boutelle, M.G.; Fillenz, M. The physiologically induced release of ascorbate in rat brain is dependent on impulse traffic, calcium influx and glutamate uptake. Neuroscience 1994, 62, 87-91. [CrossRef]
109. Rebec, G.V.; Pierce, R.C. A vitamin as neuromodulator: Ascorbate release into the extracellular fluid of the brain regulates dopaminergic and glutamatergic transmission. Prog. Neurobiol. 1994, 43, 537-565. [CrossRef]
110. Bell, J.A.; Beglan, C.L.; London, E.D. Interaction of ascorbic acid with the neurotoxic effects of NMDA and sodium nitroprusside. Life Sci. 1996, 58, 367-371. [CrossRef]
111. Lane, D.J.; Lawen, A. The glutamate aspartate transporter (GLAST) mediates L-glutamate-stimulated ascorbate-release via swelling-activated anion channels in cultured neonatal rodent astrocytes. Cell Biochem. Biophys. 2013, 65, 107-119. [CrossRef] [PubMed]
112. Cammack, J.; Ghasemzadeh, B.; Adams, R.N. The pharmacological profile of glutamate-evoked ascorbic acid efflux measured by in vivo electrochemistry. Brain Res. 1991, 565, 17-22. [CrossRef]
113. Siushansian, R.; Dixon, S.J.; Wilson, J.X. Osmotic swelling stimulates ascorbate efflux from cerebral astrocytes. J. Neurochem. 1996, 66, 1227-1233. [CrossRef] [PubMed]
114. Corti, A.; Casini, A.F.; Pompella, A. Cellular pathways for transport and efflux of ascorbate and dehydroascorbate. Arch. Biochem. Biophys. 2010, 500, 107-115. [CrossRef] [PubMed]
115. Ekholm, A.; Katsura, K.; Kristian, T.; Liu, M.; Folbergrova, J.; Siesjo, B.K. Coupling of cellular energy state and ion homeostasis during recovery following brain ischemia. Brain Res. 1993, 604, 185-191. [CrossRef]
116. Ahmad, S.; Evans, W.H. Post-translational integration and oligomerization of connexin 26 in plasma membranes and evidence of formation of membrane pores: Implications for the assembly of gap junctions. Biochem. J. 2002, 365, 693-699. [CrossRef] [PubMed]
117. Locke, D.; Koreen, I.V.; Liu, J.Y.; Harris, A.L. Reversible pore block of connexin channels by cyclodextrins. J. Biol. Chem. 2004, 279, 22883-22892. [CrossRef] [PubMed]
118. Ramundo-Orlando, A.; Serafino, A.; Schiavo, R.; Liberti, M.; d'Inzeo, G. Permeability changes of connexin32 hemi channels reconstituted in liposomes induced by extremely low frequency, low amplitude magnetic fields. BBA Biomembr. 2005, 1668, 33-40. [CrossRef] [PubMed]
119. Von Zastrow, M.; Tritton, T.R.; Castle, J.D. Identification of L-ascorbic acid in secretion granules of the rat parotid gland. J. Biol. Chem. 1984, 259, 11746-11750. [PubMed]
120. Kivirikko, K.I.; Prockop, D.J. Hydroxylation of proline in synthetic polypeptides with purified protocollagen hydroxylase. J. Biol. Chem. 1967, 242, 4007-4012. [PubMed]
121. Kivirikko, K.I.; Prockop, D.J. Enzymatic hydroxylation of proline and lysine in protocollagen. Proc. Nat. Acad. Sci. USA 1967, 57, 782-789. [CrossRef] [PubMed]
122. Kivirikko, K.I.; Prockop, D.J. Partial characterization of protocollagen from embryonic cartilage. Biochem. J. 1967, 102, 432-442. [CrossRef] [PubMed]
123. Peterkofsky, B. Ascorbate requirement for hydroxylation and secretion of procollagen: Relationship to inhibition of collagen synthesis in scurvy. Am. J. Clin. Nutr. 1991, 54, 1135S-1140S. [PubMed]
124. Padh, H. Cellular functions of ascorbic acid. Biochem. Cell Biol. 1990, 68, 1166-1173. [CrossRef] [PubMed]
125. Levine, M.; Wang, Y.; Rumsey, S.C. Analysis of ascorbic acid and dehydroascorbic acid in biological samples. Methods Enzymol. 1999, 299, 65-76. [PubMed]
126. Chatterjee, I.B.; Majumder, A.K.; Nandi, B.K.; Subramanian, N. Synthesis and some major functions of vitamin C in animals. Ann. N. Y. Acad. Sci. 1975, 258, 24-47. [CrossRef] [PubMed]
127. Padayatty, S.J.; Levine, M. Vitamin C and coronary microcirculation. Circulation 2001, 103, E117. [CrossRef] [PubMed]
128. Verrax, J.; Calderon, P.B. The controversial place of vitamin C in cancer treatment. Biochem. Pharmacol. 2008, 76, 1644-1652. [CrossRef] [PubMed]
129. Traber, M.G.; Stevens, J.F. Vitamins C and E: Beneficial effects from a mechanistic perspective. Free Radic. Biol. Med. 2011, 51, 1000-1013. [CrossRef] [PubMed]
130. Tveden-Nyborg, P.; Johansen, L.K.; Raida, Z.; Villumsen, C.K.; Larsen, J.O.; Lykkesfeldt, J. Vitamin C deficiency in early postnatal life impairs spatial memory and reduces the number of hippocampal neurons in guinea pigs. Am. J. Clin. Nutr. 2009, 90, 540-546. [CrossRef] [PubMed]
131. Lykkesfeldt, J.; Trueba, G.P.; Poulsen, H.E.; Christen, S. Vitamin C deficiency in weanling guinea pigs: Differential expression of oxidative stress andDNArepair in liver and brain. Br. J. Nutr. 2007, 98, 1116-1119. [CrossRef] [PubMed]
132. Kratzing, C.C.; Kelly, J.D.; Kratzing, J.E. Ascorbic acid in fetal rat brain. J. Neurochem. 1985, 44, 1623-1624. [CrossRef] [PubMed]
133. Tveden-Nyborg, P.; Vogt, L.; Schjoldager, J.G.; Jeannet, N.; Hasselholt, S.; Paidi, M.D.; Christen, S.; Lykkesfeldt, J. Maternal vitamin C deficiency during pregnancy persistently impairs hippocampal neurogenesis in offspring of guinea pigs. PLoS ONE 2012, 7, e48488. [CrossRef] [PubMed]
134. Sotiriou, S.; Gispert, S.; Cheng, J.; Wang, Y.; Chen, A.; Hoogstraten-Miller, S.; Miller, G.F.; Kwon, O.; Levine, M.; Guttentag, S.H.; et al. Ascorbic-acid transporter Slc23a1 is essential for vitamin C transport into the brain and for perinatal survival. Nat. Med. 2002, 8, 514-517. [CrossRef] [PubMed]
135. Naseer, M.I.; Ullah, N.; Ullah, I.; Koh, P.O.; Lee, H.Y.; Park, M.S.; Kim, M.O. Vitamin C protects against ethanol and PTZ-induced apoptotic neurodegeneration in prenatal rat hippocampal neurons. Synapse 2011, 65, 562-571. [CrossRef] [PubMed]
136. Niki, E. Action of ascorbic acid as a scavenger of active and stable oxygen radicals. Am. J. Clin. Nutr. 1991, 54, 1119S-1124S. [PubMed]
137. Santos, I.M.; Tome Ada, R.; Saldanha, G.B.; Ferreira, P.M.; Militao, G.C.; Freitas, R.M. Oxidative stress in the hippocampus during experimental seizures can be ameliorated with the antioxidant ascorbic acid. Oxid. Med. Cell. Longev. 2009, 2, 214-221. [CrossRef] [PubMed]
138. Qiu, S.; Li, L.; Weeber, E.J.; May, J.M. Ascorbate transport by primary cultured neurons and its role in neuronal function and protection against excitotoxicity. J. Neurosci. Res. 2007, 85, 1046-1056. [CrossRef] [PubMed]
139. Coyle, J.T.; Puttfarcken, P. Oxidative stress, glutamate, and neurodegenerative disorders. Science 1993, 262, 689-695. [CrossRef] [PubMed]
140. Lipton, S.A.; Rosenberg, P.A. Excitatory amino acids as a final common pathway for neurologic disorders. N. Engl. J. Med. 1994, 330, 613-622. [PubMed]
141. Choi, D.W. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1988, 1, 623-634. [CrossRef]
142. Todd, R.D.; Bauer, P.A. Ascorbate modulates 5-[3H]hydroxytryptamine binding to central 5-HT3 sites in bovine frontal cortex. J. Neurochem. 1988, 50, 1505-1512. [CrossRef] [PubMed]
143. Majewska, M.D.; Bell, J.A. Ascorbic acid protects neurons from injury induced by glutamate and NMDA. Neuroreport 1990, 1, 194-196. [CrossRef] [PubMed]
144. Majewska, M.D.; Bell, J.A.; London, E.D. Regulation of the NMDA receptor by redox phenomena: Inhibitory role of ascorbate. Brain Res. 1990, 537, 328-332. [CrossRef]
145. Levine, M.; Morita, K.; Heldman, E.; Pollard, H.B. Ascorbic acid regulation of norepinephrine biosynthesis in isolated chromaffin granules from bovine adrenal medulla. J. Biol. Chem. 1985, 260, 15598-15603. [PubMed]
146. Levine, M.; Morita, K.; Pollard, H. Enhancement of norepinephrine biosynthesis by ascorbic acid in cultured bovine chromaffin cells. J. Biol. Chem. 1985, 260, 12942-12947. [PubMed]
147. Paterson, I.A.; Hertz, L. Sodium-independent transport of noradrenaline in mouse and rat astrocytes in primary culture. J. Neurosci. Res. 1989, 23, 71-77. [CrossRef] [PubMed]
148. Atlante, A.; Gagliardi, S.; Minervini, G.M.; Ciotti, M.T.; Marra, E.; Calissano, P. Glutamate neurotoxicity in rat cerebellar granule cells: A major role for xanthine oxidase in oxygen radical formation. J. Neurochem. 1997, 68, 2038-2045. [CrossRef] [PubMed]
149. Kuo, C.H.; Hata, F.; Yoshida, H.; Yamatodani, A.;Wada, H. Effect of ascorbic acid on release of acetylcholine from synaptic vesicles prepared from different species of animals and release of noradrenaline from synaptic vesicles of rat brain. Life Sci. 1979, 24, 911-915. [CrossRef]
150. Fan, S.F.; Yazulla, S. Modulation of voltage-dependent k+ currents (Ik(v)) in retinal bipolar cells by ascorbate is mediated by dopamine d1 receptors. Vis. Neurosci. 1999, 16, 923-931. [CrossRef] [PubMed]
151. Nelson, M.T.; Joksovic, P.M.; Su, P.; Kang, H.W.; Van Deusen, A.; Baumgart, J.P.; David, L.S.; Snutch, T.P.; Barrett, P.Q.; Lee, J.H.; et al. Molecular mechanisms of subtype-specific inhibition of neuronal t-type calcium channels by ascorbate. J. Neurosci. 2007, 27, 12577-12583. [CrossRef] [PubMed]
152. Calero, C.I.; Vickers, E.; Moraga Cid, G.; Aguayo, L.G.; von Gersdorff, H.; Calvo, D.J. Allosteric modulation of retinal GABA receptors by ascorbic acid. J. Neurosci. 2011, 31, 9672-9682. [CrossRef] [PubMed]
153. Eldridge, C.F.; Bunge, M.B.; Bunge, R.P.; Wood, P.M. Differentiation of axon-related schwann cells in vitro. I. Ascorbic acid regulates basal lamina assembly and myelin formation. J. Cell Biol. 1987, 105, 1023-1034. [CrossRef] [PubMed]
154. Araque, A.; Parpura, V.; Sanzgiri, R.P.; Haydon, P.G. Tripartite synapses: Glia, the unacknowledged partner. Trends Neurosci. 1999, 22, 208-215. [CrossRef]
155. Pellerin, L.; Magistretti, P.J. Glutamate uptake into astrocytes stimulates aerobic glycolysis: A mechanism coupling neuronal activity to glucose utilization. Proc. Natl. Acad. Sci. USA 1994, 91, 10625-10629. [CrossRef] [PubMed]
156. Demestre, M.; Boutelle, M.; Fillenz, M. Stimulated release of lactate in freely moving rats is dependent on the uptake of glutamate. J. Physiol. 1997, 499, 825-832. [CrossRef] [PubMed]
157. Magistretti, P.J.; Pellerin, L. The astrocyte-mediated coupling between synaptic activity and energy metabolism operates through volume transmission. Prog. Brain Res. 2000, 125, 229-240. [PubMed]
158. Allaman, I.; Gavillet, M.; Belanger, M.; Laroche, T.; Viertl, D.; Lashuel, H.A.; Magistretti, P.J. Amyloid-β aggregates cause alterations of astrocytic metabolic phenotype: Impact on neuronal viability. J. Neurosci. 2010, 30, 3326-3338. [CrossRef] [PubMed]
159. Bittar, P.G.; Charnay, Y.; Pellerin, L.; Bouras, C.; Magistretti, P.J. Selective distribution of lactate dehydrogenase isoenzymes in neurons and astrocytes of human brain. J. Cereb. Blood Flow Metab. 1996, 16, 1079-1089. [CrossRef] [PubMed]
160. Laughton, J.D.; Charnay, Y.; Belloir, B.; Pellerin, L.; Magistretti, P.J.; Bouras, C. Differential messenger RNA distribution of lactate dehydrogenase LDH-1 and LDH-5 isoforms in the rat brain. Neuroscience 2000, 96, 619-625. [CrossRef]
161. Pellerin, L.; Bergersen, L.H.; Halestrap, A.P.; Pierre, K. Cellular and subcellular distribution of monocarboxylate transporters in cultured brain cells and in the adult brain. J. Neurosci. Res. 2005, 79, 55-64. [CrossRef] [PubMed]
162. Pierre, K.; Pellerin, L. Monocarboxylate transporters in the central nervous system: Distribution, regulation and function. J. Neurochem. 2005, 94, 1-14. [CrossRef] [PubMed]
163. Chih, C.P.; Roberts, E.L., Jr. Energy substrates for neurons during neural activity: A critical review of the astrocyte-neuron lactate shuttle hypothesis. J. Cereb. Blood Flow Metab. 2003, 23, 1263-1281. [CrossRef] [PubMed]
164. Dienel, G.A.; Wang, R.Y.; Cruz, N.F. Generalized sensory stimulation of conscious rats increases labeling of oxidative pathways of glucose metabolism when the brain glucose-oxygen uptake ratio rises. J. Cereb. Blood Flow Metab. 2002, 22, 1490-1502. [CrossRef] [PubMed]
165. Gjedde, A. Cerebral blood flow change in arterial hypoxemia is consistent with negligible oxygen tension in brain mitochondria. Neuroimage 2002, 17, 1876-1881. [PubMed]
166. Hertz, L. The astrocyte-neuron lactate shuttle: A challenge of a challenge. J. Cereb. Blood Flow Metab. 2004, 24, 1241-1248. [CrossRef] [PubMed]
167. Hertz, L.; Kala, G. Energy metabolism in brain cells: Effects of elevated ammonia concentrations. Metab. Brain Dis. 2007, 22, 199-218. [CrossRef] [PubMed]
168. Mangia, S.; Garreffa, G.; Bianciardi, M.; Giove, F.; di Salle, F.; Maraviglia, B. The aerobic brain: Lactate decrease at the onset of neural activity. Neuroscience 2003, 118, 7-10. [CrossRef]
169. Mangia, S.; Giove, F.; Bianciardi, M.; di Salle, F.; Garreffa, G.; Maraviglia, B. Issues concerning the construction of a metabolic model for neuronal activation. J. Neurosci Res. 2003, 71, 463-467. [CrossRef] [PubMed]
170. Mangia, S.; Simpson, I.A.; Vannucci, S.J.; Carruthers, A. The in vivo neuron-to-astrocyte lactate shuttle in human brain: Evidence from modeling of measured lactate levels during visual stimulation. J. Neurochem. 2009, 109 (Suppl. 1), 55-62. [CrossRef] [PubMed]
171. Beltrán, F.A.; Acuña, A.I.; Miro, M.P.; Angulo, C.; Concha, I.I.; Castro, M.A. Ascorbic acid-dependent GLUT3 inhibition is a critical step for switching neuronal metabolism. J. Cell. Physiol. 2011, 226, 3286-3294. [CrossRef] [PubMed]
172. Covarrubias-Pinto, A.; Moll, P.; Solis-Maldonado, M.; Acuña, A.I.; Riveros, A.; Paz Miro, M.; Papic, E.; Beltrán, F.A.; Cepeda, C.; Concha, I.I.; et al. Beyond the redox imbalance: Oxidative stress contributes to an impaired GLUT3 modulation in huntington's disease. Free Radic. Biol. Med. 2015. [CrossRef] [PubMed]
173. Mink, J.W.; Blumenschine, R.J.; Adams, D.B. Ratio of central nervous system to body metabolism in vertebrates: Its constancy and functional basis. Am. J. Physiol. 1981, 241, R203-R212. [PubMed]
174. Abeles, M. Corticonics: Neural Circuits of the Cerebral Cortex; Cambridge University Press: New York, NY, USA, 1991; p. 280.
175. Braitenberg, V.; Schüz, A. Cortex: Statistics and Geometry of Neuronal Connectivity; Springer: Berlin, Germany, 1998.
176. Sibson, N.R.; Dhankhar, A.; Mason, G.F.; Rothman, D.L.; Behar, K.L.; Shulman, R.G. Stoichiometric coupling of brain glucose metabolism and glutamatergic neuronal activity. Proc. Natl. Acad. Sci. USA 1998, 95, 316-321. [CrossRef] [PubMed]
177. Sokoloff, L.; Reivich, M.; Kennedy, C.; Des Rosiers, M.H.; Patlak, C.S.; Pettigrew, K.D.; Sakurada, O.; Shinohara, M. The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: Theory, procedure, and normal values in the conscious and anesthetized albino rat. J. Neurochem. 1977, 28, 897-916. [CrossRef] [PubMed]
178. Giove, F.; Mangia, S.; Bianciardi, M.; Garreffa, G.; di Salle, F.; Morrone, R.; Maraviglia, B. The physiology and metabolism of neuronal activation: In vivo studies by NMR and other methods. Magn. Reson. Imaging 2003, 21, 1283-1293. [CrossRef] [PubMed]
179. Boado, R.J.; Pardridge, W.M. Measurement of blood-brain barrier glut1 glucose transporter and actin mRNA by a quantitative polymerase chain reaction assay. J. Neurochem. 1994, 62, 2085-2090. [CrossRef] [PubMed]
180. Bolz, S.; Farrell, C.L.; Dietz, K.;Wolburg, H. Subcellular distribution of glucose transporter (GLUT-1) during development of the blood-brain barrier in rats. Cell Tissue Res. 1996, 284, 355-365. [CrossRef] [PubMed]
181. Nualart, F.; Godoy, A.; Reinicke, K. Expression of the hexose transporters GLUT1 and GLUT2 during the early development of the human brain. Brain Res. 1999, 824, 97-104. [CrossRef]
182. Maher, F.; Vannucci, S.; Takeda, J.; Simpson, I.A. Expression of mouse-GLUT3 and human-GLUT3 glucose transporter proteins in brain. Biochem. Biophys. Res. Commun. 1992, 182, 703-711. [CrossRef]
183. Lowry, O.H.; Passonneau, J.V. The relationships between substrates and enzymes of glycolysis in brain. J. Biol. Chem. 1964, 239, 31-42. [PubMed]
184. Beltrán, F.A.; Acuña, A.I.; Miró, M.P.; Castro, M. Brain energy metabolism in health and disease. In Neuroscience-Dealing with Frontiers; Contreras, C.M., Ed. InTech: Rijeka, Croatia, 2012; p. 32.
185. Kety, S.S. The general metabolism of the brain in vivo. In The Metabolism of the Nervous System; Richter, D., Ed.; Elsevier: Philadelphia, PA, USA, 1957; p. 17.
186. Sokoloff, L. Quantitative measurements of cerebral blood flow in man. Methods Med. Res. 1960, 8, 253-261. [PubMed]
187. Schurr, A.; West, C.A.; Rigor, B.M. Lactate-supported synaptic function in the rat hippocampal slice preparation. Science 1988, 240, 1326-1328. [CrossRef] [PubMed]
188. Izumi, Y.; Ishii, K.; Katsuki, H.; Benz, A.M.; Zorumski, C.F. β-Hydroxybutyrate fuels synaptic function during development. Histological and physiological evidence in rat hippocampal slices. J. Clin. Investing. 1998, 101, 1121-1132. [CrossRef] [PubMed]
189. Wyss, M.T.; Jolivet, R.; Buck, A.; Magistretti, P.J.;Weber, B. In vivo evidence for lactate as a neuronal energy source. J. Neurosci. 2011, 31, 7477-7485. [CrossRef] [PubMed]
190. Chinopoulos, C.; Adam-Vizi, V. Mitochondria deficient in complex I activity are depolarized by hydrogen peroxide in nerve terminals: Relevance to parkinson's disease. J. Neurochem. 2001, 76, 302-306. [CrossRef] [PubMed]
191. Dawson, V.L.; Dawson, T.M.; London, E.D.; Bredt, D.S.; Snyder, S.H. Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures. Proc. Natl. Acad. Sci. USA 1991, 88, 6368-6371. [CrossRef] [PubMed]
192. Lafon-Cazal, M.; Pietri, S.; Culcasi, M.; Bockaert, J. NMDA-dependent superoxide production and neurotoxicity. Nature 1993, 364, 535-537. [CrossRef] [PubMed]
193. Bondy, S.C.; Lee, D.K. Oxidative stress induced by glutamate receptor agonists. Brain Res. 1993, 610, 229-233. [CrossRef]
194. Vesce, S.; Kirk, L.; Nicholls, D.G. Relationships between superoxide levels and delayed calcium deregulation in cultured cerebellar granule cells exposed continuously to glutamate. J. Neurochem. 2004, 90, 683-693. [CrossRef] [PubMed]
195. Kahlert, S.; Zundorf, G.; Reiser, G. Glutamate-mediated influx of extracellular Ca2+ is coupled with reactive oxygen species generation in cultured hippocampal neurons but not in astrocytes. J. Neurosci. Res. 2005, 79, 262-271. [CrossRef] [PubMed]
196. Neymotin, A.; Petri, S.; Calingasan, N.Y.; Wille, E.; Schafer, P.; Stewart, C.; Hensley, K.; Beal, M.F.; Kiaei, M. Lenalidomide (revlimid) administration at symptom onset is neuroprotective in a mouse model of amyotrophic lateral sclerosis. Exp. Neurol. 2009, 220, 191-197. [CrossRef] [PubMed]
197. Shaw, P.J. Molecular and cellular pathways of neurodegeneration in motor neurone disease. J. Neurol. Neurosurg. Psychiatry 2005, 76, 1046-1057. [CrossRef] [PubMed]
198. Rosen, D.R.; Siddique, T.; Patterson, D.; Figlewicz, D.A.; Sapp, P.; Hentati, A.; Donaldson, D.; Goto, J.; O'Regan, J.P.; Deng, H.X.; et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993, 362, 59-62. [CrossRef] [PubMed]
199. Lin, M.T.; Beal, M.F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006, 443, 787-795. [CrossRef] [PubMed]
200. Mattiazzi, M.; D'Aurelio, M.; Gajewski, C.D.; Martushova, K.; Kiaei, M.; Beal, M.F.; Manfredi, G. Mutated human sod1 causes dysfunction of oxidative phosphorylation in mitochondria of transgenic mice. J. Biol. Chem. 2002, 277, 29626-29633. [CrossRef] [PubMed]
201. Orth, M.; Schapira, A.H. Mitochondria and degenerative disorders. Am. J. Med. Genet. 2001, 106, 27-36. [CrossRef] [PubMed]
202. Wenk, G.L. Neuropathologic changes in alzheimer's disease. J. Clin. Psychiatry 2003, 64, 7-10. [PubMed]
203. Duyckaerts, C.; Delatour, B.; Potier, M.C. Classification and basic pathology of alzheimer disease. Acta Neuropathol. 2009, 118, 5-36. [CrossRef] [PubMed]
204. Anandatheerthavarada, H.K.; Devi, L. Amyloid precursor protein and mitochondrial dysfunction in alzheimer's disease. Neuroscientist 2007, 13, 626-638. [CrossRef] [PubMed]
205. Gu, M.; Gash, M.T.; Mann, V.M.; Javoy-Agid, F.; Cooper, J.M.; Schapira, A.H. Mitochondrial defect in huntington's disease caudate nucleus. Ann. Neurol. 1996, 39, 385-389. [CrossRef] [PubMed]
206. Moreira, P.I.; Santos, M.S.; Oliveira, C.R. Alzheimer's disease: A lesson from mitochondrial dysfunction. Antioxid. Redox Signal. 2007, 9, 1621-1630. [CrossRef] [PubMed]
207. Swerdlow, R.H.; Khan, S.M. The alzheimer's disease mitochondrial cascade hypothesis: An update. Exp. Neurol. 2009, 218, 308-315. [CrossRef] [PubMed]
208. Gabuzda, D.; Busciglio, J.; Chen, L.B.; Matsudaira, P.; Yankner, B.A. Inhibition of energy metabolism alters the processing of amyloid precursor protein and induces a potentially amyloidogenic derivative. J. Biol. Chem. 1994, 269, 13623-13628. [PubMed]
209. Apelt, J.; Bigl, M.; Wunderlich, P.; Schliebs, R. Aging-related increase in oxidative stress correlates with developmental pattern of β-secretase activity and β-amyloid plaque formation in transgenic TG2576 mice with alzheimer-like pathology. Int. J. Dev. Neurosci. 2004, 22, 475-484. [CrossRef] [PubMed]
210. Hefti, F.; Goure, W.F.; Jerecic, J.; Iverson, K.S.; Walicke, P.A.; Krafft, G.A. The case for soluble Aβ oligomers as a drug target in alzheimer's disease. Trends Pharmacol. Sci. 2013, 34, 261-266. [CrossRef] [PubMed]
211. Sanmartin, C.D.; Adasme, T.; Hidalgo, C.; Paula-Lima, A.C. The antioxidant N-acetylcysteine prevents the mitochondrial fragmentation induced by soluble amyloid-β peptide oligomers. Neurodegener. Dis. 2012, 10, 34-37. [CrossRef] [PubMed]
212. Bush, A.I.; Masters, C.L.; Tanzi, R.E. Copper, β-amyloid, and alzheimer's disease: Tapping a sensitive connection. Proc. Natl. Acad. Sci. USA 2003, 100, 11193-11194. [CrossRef] [PubMed]
213. Ma, T.; Hoeffer, C.A.; Wong, H.; Massaad, C.A.; Zhou, P.; Iadecola, C.; Murphy, M.P.; Pautler, R.G.; Klann, E. Amyloid β-induced impairments in hippocampal synaptic plasticity are rescued by decreasing mitochondrial superoxide. J. Neurosci. 2011, 31, 5589-5595. [CrossRef] [PubMed]
214. Harrison, F.E.; Hosseini, A.H.; McDonald, M.P.; May, J.M. Vitamin C reduces spatial learning deficits in middle-aged and very old app/psen1 transgenic and wild-type mice. Pharmacol. Biochem. Behav. 2009, 93, 443-450. [CrossRef] [PubMed]
215. Kennard, J.A.; Harrison, F.E. Intravenous ascorbate improves spatial memory in middle-aged APP/PSEN1 and wild type mice. Behav. Brain Res. 2014, 264, 34-42. [CrossRef] [PubMed]
216. Murakami, K.; Murata, N.; Ozawa, Y.; Kinoshita, N.; Irie, K.; Shirasawa, T.; Shimizu, T. Vitamin C restores behavioral deficits and amyloid-β oligomerization without affecting plaque formation in a mouse model of alzheimer's disease. J. Alzheimer's Dis. 2011, 26, 7-18.
217. Kook, S.Y.; Lee, K.M.; Kim, Y.; Cha, M.Y.; Kang, S.; Baik, S.H.; Lee, H.; Park, R.; Mook-Jung, I. High-dose of vitamin C supplementation reduces amyloid plaque burden and ameliorates pathological changes in the brain of 5XFAD mice. Cell Death Dis. 2014, 5, e1083. [CrossRef] [PubMed]
218. Charlton, K.E.; Rabinowitz, T.L.; Geffen, L.N.; Dhansay, M.A. Lowered plasma vitamin C, but not vitamin e, concentrations in dementia patients. J. Nutr. Health Aging 2004, 8, 99-107. [PubMed]
219. Riviere, S.; Birlouez-Aragon, I.; Nourhashemi, F.; Vellas, B. Low plasma vitamin C in alzheimer patients despite an adequate diet. Int. J. Geriatr. Psychiatry 1998, 13, 749-754. [CrossRef]
220. Zandi, P.P.; Anthony, J.C.; Khachaturian, A.S.; Stone, S.V.; Gustafson, D.; Tschanz, J.T.; Norton, M.C.; Welsh-Bohmer, K.A.; Breitner, J.C.; Cache County Study, G. Reduced risk of alzheimer disease in users of antioxidant vitamin supplements: The cache county study. Arch. Neurol. 2004, 61, 82-88. [CrossRef] [PubMed]
221. DiFiglia, M. Excitotoxic injury of the neostriatum: A model for huntington's disease. Trends Neurosci. 1990, 13, 286-289. [CrossRef]
222. Twelvetrees, A.E.; Yuen, E.Y.; Arancibia-Carcamo, I.L.; MacAskill, A.F.; Rostaing, P.; Lumb, M.J.; Humbert, S.; Triller, A.; Saudou, F.; Yan, Z.; et al. Delivery of GABAARs to synapses is mediated by HAP1-KIF5 and disrupted by mutant huntingtin. Neuron 2010, 65, 53-65. [CrossRef] [PubMed]
223. Caviston, J.P.; Holzbaur, E.L. Huntingtin as an essential integrator of intracellular vesicular trafficking. Trends Cell Biol. 2009, 19, 147-155. [CrossRef] [PubMed]
224. Bamford, K.A.; Caine, E.D.; Kido, D.K.; Cox, C.; Shoulson, I. A prospective evaluation of cognitive decline in early huntington's disease: Functional and radiographic correlates. Neurology 1995, 45, 1867-1873. [CrossRef] [PubMed]
225. Brandt, J.; Folstein, S.E.; Folstein, M.F. Differential cognitive impairment in alzheimer's disease and huntington's disease. Ann. Neurol. 1988, 23, 555-561. [CrossRef] [PubMed]
226. Shiwach, R. Psychopathology in huntington's disease patients. Acta Psychiatr. Scand. 1994, 90, 241-246. [CrossRef] [PubMed]
227. Bruyn, G.W.; vonWolferen, W.J. Pathogenesis of huntington's chorea. Lancet 1973, 1, 1382. [CrossRef]
228. Hersch, S.M.; Gevorkian, S.; Marder, K.; Moskowitz, C.; Feigin, A.; Cox, M.; Como, P.; Zimmerman, C.; Lin, M.; Zhang, L.; et al. Creatine in huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology 2006, 66, 250-252. [CrossRef] [PubMed]
229. Browne, S.E.; Ferrante, R.J.; Beal, M.F. Oxidative stress in huntington's disease. Brain Pathol. 1999, 9, 147-163. [CrossRef] [PubMed]
230. Browne, S.E.; Beal, M.F. Oxidative damage in huntington's disease pathogenesis. Antioxid. Redox Signal. 2006, 8, 2061-2073. [CrossRef] [PubMed]
231. Sorolla, M.A.; Reverter-Branchat, G.; Tamarit, J.; Ferrer, I.; Ros, J.; Cabiscol, E. Proteomic and oxidative stress analysis in human brain samples of huntington disease. Free Radic. Biol. Med. 2008, 45, 667-678. [CrossRef] [PubMed]
232. Santamaria, A.; Perez-Severiano, F.; Rodriguez-Martinez, E.; Maldonado, P.D.; Pedraza-Chaverri, J.; Rios, C.; Segovia, J. Comparative analysis of superoxide dismutase activity between acute pharmacological models and a transgenic mouse model of huntington's disease. Neurochem. Res. 2001, 26, 419-424. [CrossRef] [PubMed]
233. Gines, S.; Seong, I.S.; Fossale, E.; Ivanova, E.; Trettel, F.; Gusella, J.F.; Wheeler, V.C.; Persichetti, F.; MacDonald, M.E. Specific progressive camp reduction implicates energy deficit in presymptomatic huntington's disease knock-in mice. Hum. Mol. Genet. 2003, 12, 497-508. [CrossRef] [PubMed]
234. Kuwert, T.; Lange, H.W.; Boecker, H.; Titz, H.; Herzog, H.; Aulich, A.; Wang, B.C.; Nayak, U.; Feinendegen, L.E. Striatal glucose consumption in chorea-free subjects at risk of huntington's disease. J. Neurol. 1993, 241, 31-36. [CrossRef] [PubMed]
235. Leenders, K.L.; Frackowiak, R.S.; Quinn, N.; Marsden, C.D. Brain energy metabolism and dopaminergic function in huntington's disease measured in vivo using positron emission tomography. Mov. Disord. 1986, 1, 69-77. [CrossRef] [PubMed]
236. Powers, W.J.; Videen, T.O.; Markham, J.; McGee-Minnich, L.; Antenor-Dorsey, J.V.; Hershey, T.; Perlmutter, J.S. Selective defect of in vivo glycolysis in early huntington's disease striatum. Proc. Natl. Acad. Sci. USA 2007, 104, 2945-2949. [CrossRef] [PubMed]
237. Benchoua, A.; Trioulier, Y.; Zala, D.; Gaillard, M.C.; Lefort, N.; Dufour, N.; Saudou, F.; Elalouf, J.M.; Hirsch, E.; Hantraye, P.; et al. Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated huntingtin. Mol. Biol. Cell 2006, 17, 1652-1663. [CrossRef] [PubMed]
238. Brennan, W.A., Jr.; Bird, E.D.; Aprille, J.R. Regional mitochondrial respiratory activity in huntington's disease brain. J. Neurochem. 1985, 44, 1948-1950. [CrossRef] [PubMed]
239. Browne, S.E. Mitochondria and huntington's disease pathogenesis: Insight from genetic and chemical models. Ann. N. Y. Acad. Sci. 2008, 1147, 358-382. [CrossRef] [PubMed]
240. Lim, D.; Fedrizzi, L.; Tartari, M.; Zuccato, C.; Cattaneo, E.; Brini, M.; Carafoli, E. Calcium homeostasis and mitochondrial dysfunction in striatal neurons of huntington disease. J. Biol. Chem. 2008, 283, 5780-5789. [CrossRef] [PubMed]
241. Milakovic, T.; Johnson, G.V. Mitochondrial respiration and ATP production are significantly impaired in striatal cells expressing mutant huntingtin. J. Biol. Chem. 2005, 280, 30773-30782. [CrossRef] [PubMed]
242. Tabrizi, S.J.; Cleeter, M.W.; Xuereb, J.; Taanman, J.W.; Cooper, J.M.; Schapira, A.H. Biochemical abnormalities and excitotoxicity in huntington's disease brain. Ann. Neurol. 1999, 45, 25-32. [CrossRef]
243. Damiano, M.; Galvan, L.; Deglon, N.; Brouillet, E. Mitochondria in huntington's disease. BBA Mol. Basis Dis. 2010, 1802, 52-61. [CrossRef] [PubMed]
244. Parker, W.D., Jr.; Boyson, S.J.; Luder, A.S.; Parks, J.K. Evidence for a defect in NADH: Ubiquinone oxidoreductase (complex I) in huntington's disease. Neurology 1990, 40, 1231-1234. [CrossRef] [PubMed]
245. Brouillet, E.; Conde, F.; Beal, M.F.; Hantraye, P. Replicating huntington's disease phenotype in experimental animals. Prog. Neurobiol. 1999, 59, 427-468. [CrossRef]
246. Ruan, Q.; Lesort, M.; MacDonald, M.E.; Johnson, G.V. Striatal cells from mutant huntingtin knock-in mice are selectively vulnerable to mitochondrial complex II inhibitor-induced cell death through a non-apoptotic pathway. Hum. Mol. Genet. 2004, 13, 669-681. [CrossRef] [PubMed]
247. Choo, Y.S.; Johnson, G.V.; MacDonald, M.; Detloff, P.J.; Lesort, M. Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Hum. Mol. Genet. 2004, 13, 1407-1420. [CrossRef] [PubMed]
248. Panov, A.V.; Gutekunst, C.A.; Leavitt, B.R.; Hayden, M.R.; Burke, J.R.; Strittmatter, W.J.; Greenamyre, J.T. Early mitochondrial calcium defects in huntington's disease are a direct effect of polyglutamines. Nat. Neurosci. 2002, 5, 731-736. [CrossRef] [PubMed]
249. Petrasch-Parwez, E.; Nguyen, H.P.; Lobbecke-Schumacher, M.; Habbes, H.W.; Wieczorek, S.; Riess, O.; Andres, K.H.; Dermietzel, R.; von Horsten, S. Cellular and subcellular localization of huntingtin [corrected] aggregates in the brain of a rat transgenic for huntington disease. J. Comp. Neurol. 2007, 501, 716-730. [CrossRef] [PubMed]
250. Cui, L.; Jeong, H.; Borovecki, F.; Parkhurst, C.N.; Tanese, N.; Krainc, D. Transcriptional repression of PGC-1α by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 2006, 127, 59-69. [CrossRef] [PubMed]
251. McGill, J.K.; Beal, M.F. PGC-1α, a new therapeutic target in huntington's disease? Cell 2006, 127, 465-468. [CrossRef] [PubMed]
252. St-Pierre, J.; Drori, S.; Uldry, M.; Silvaggi, J.M.; Rhee, J.; Jager, S.; Handschin, C.; Zheng, K.; Lin, J.; Yang,W.; et al. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 2006, 127, 397-408. [CrossRef] [PubMed]
253. Rebec, G.V.; Barton, S.J.; Marseilles, A.M.; Collins, K. Ascorbate treatment attenuates the huntington behavioral phenotype in mice. Neuroreport 2003, 14, 1263-1265. [CrossRef] [PubMed]
254. Dorner, J.L.; Miller, B.R.; Klein, E.L.; Murphy-Nakhnikian, A.; Andrews, R.L.; Barton, S.J.; Rebec, G.V. Corticostriatal dysfunction underlies diminished striatal ascorbate release in the R6/2 mouse model of huntington's disease. Brain Res. 2009, 1290, 111-120. [CrossRef] [PubMed]
255. Rebec, G.V.; Conroy, S.K.; Barton, S.J. Hyperactive striatal neurons in symptomatic huntington R6/2 mice: Variations with behavioral state and repeated ascorbate treatment. Neuroscience 2006, 137, 327-336. [CrossRef] [PubMed]
256. Hirsch, E.C.; Jenner, P.; Przedborski, S. Pathogenesis of parkinson's disease. Mov. Disord. 2013, 28, 24-30. [CrossRef] [PubMed]
257. Braak, H.; del Tredici, K.; Rub, U.; de Vos, R.A.; Jansen Steur, E.N.; Braak, E. Staging of brain pathology related to sporadic parkinson's disease. Neurobiol. Aging 2003, 24, 197-211. [CrossRef]
258. Booij, J.; Tissingh, G.; Boer, G.J.; Speelman, J.D.; Stoof, J.C.; Janssen, A.G.; Wolters, E.C.; van Royen, E.A. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced parkinson's disease. J. Neurol. Neurosurg. Psychiatry 1997, 62, 133-140. [CrossRef] [PubMed]
259. Iranzo, A.; Lomena, F.; Stockner, H.; Valldeoriola, F.; Vilaseca, I.; Salamero, M.; Molinuevo, J.L.; Serradell, M.; Duch, J.; Pavia, J.; et al. Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: A prospective study [corrected]. Lancet Neurol. 2010, 9, 1070-1077. [CrossRef]
260. Kaufman, M.J.; Madras, B.K. Severe depletion of cocaine recognition sites associated with the dopamine transporter in parkinson's-diseased striatum. Synapse 1991, 9, 43-49. [CrossRef] [PubMed]
261. Biskup, S.; Gerlach, M.; Kupsch, A.; Reichmann, H.; Riederer, P.; Vieregge, P.; Wullner, U.; Gasser, T. Genes associated with parkinson syndrome. J. Neurol. 2008, 255 5, 8-17. [CrossRef] [PubMed]
262. Schapira, A.H. Mitochondrial dysfunction in neurodegenerative diseases. Neurochem. Res. 2008, 33, 2502-2509. [CrossRef] [PubMed]
263. Henchcliffe, C.; Beal, M.F. Mitochondrial biology and oxidative stress in parkinson disease pathogenesis. Nat. Clin. Pract. Neurol. 2008, 4, 600-609. [CrossRef] [PubMed]
264. Bindoff, L.A.; Birch-Machin, M.; Cartlidge, N.E.; Parker,W.D., Jr.; Turnbull, D.M. Mitochondrial function in Parkinson's disease. Lancet 1989, 2, 49. [CrossRef]
265. Mizuno, Y.; Ohta, S.; Tanaka, M.; Takamiya, S.; Suzuki, K.; Sato, T.; Oya, H.; Ozawa, T.; Kagawa, Y. Deficiencies in complex I subunits of the respiratory chain in parkinson's disease. Biochem. Biophys. Res. Commun. 1989, 163, 1450-1455. [CrossRef]
266. Schapira, A.H.; Cooper, J.M.; Dexter, D.; Jenner, P.; Clark, J.B.; Marsden, C.D. Mitochondrial complex I deficiency in parkinson's disease. Lancet 1989, 1, 1269. [CrossRef]
267. Xiang, W.; Schlachetzki, J.C.; Helling, S.; Bussmann, J.C.; Berlinghof, M.; Schaffer, T.E.; Marcus, K.; Winkler, J.; Klucken, J.; Becker, C.M. Oxidative stress-induced posttranslational modifications of α-synuclein: Specific modification of α-synuclein by 4-hydroxy-2-nonenal increases dopaminergic toxicity. Mol. Cell. Neurosci. 2013, 54, 71-83. [CrossRef] [PubMed]
268. Khan, S.; Jyoti, S.; Naz, F.; Shakya, B.; Rahul; Afzal, M.; Siddique, Y.H. Effect of L-ascorbic acid on the climbing ability and protein levels in the brain of drosophila model of Parkinson's disease. Int. J. Neurosci. 2012, 122, 704-709. [CrossRef] [PubMed]
269. Ballaz, S.; Morales, I.; Rodriguez, M.; Obeso, J.A. Ascorbate prevents cell death from prolonged exposure to glutamate in an in vitro model of human dopaminergic neurons. J. Neurosci. Res. 2013, 91, 1609-1617. [CrossRef] [PubMed]
270. Foy, C.J.; Passmore, A.P.; Vahidassr, M.D.; Young, I.S.; Lawson, J.T. Plasma chain-breaking antioxidants in Alzheimer's disease, vascular dementia and parkinson's disease. QJM 1999, 92, 39-45. [CrossRef] [PubMed]
271. Sohmiya, M.; Tanaka, M.; Tak, N.W.; Yanagisawa, M.; Tanino, Y.; Suzuki, Y.; Okamoto, K.; Yamamoto, Y. Redox status of plasma coenzyme Q10 indicates elevated systemic oxidative stress in parkinson's disease. J. Neurol. Sci. 2004, 223, 161-166. [CrossRef] [PubMed]
272. Ide, K.; Yamada, H.; Umegaki, K.; Mizuno, K.; Kawakami, N.; Hagiwara, Y.; Matsumoto, M.; Yoshida, H.; Kim, K.; Shiosaki, E.; et al. Lymphocyte vitamin C levels as potential biomarker for progression of parkinson's disease. Nutrition 2015, 31, 406-408. [CrossRef] [PubMed]
273. Fitzgerald, K.C.; O'Reilly, E.J.; Fondell, E.; Falcone, G.J.; McCullough, M.L.; Park, Y.; Kolonel, L.N.; Ascherio, A. Intakes of vitamin C and carotenoids and risk of amyotrophic lateral sclerosis: Pooled results from 5 cohort studies. Ann. Neurol. 2013, 73, 236-245. [PubMed]